What Ketofan SR Treats: Main Uses and Benefits

Ketofan SR is used to provide symptomatic relief across several key areas related to chronic and acute discomfort. The active ingredient is commonly applied in conditions marked by heightened symptoms, such as osteoarthritis and rheumatoid arthritis, helping to manage associated pain, swelling, and stiffness.

Relieving Pain and Discomfort

This medication helps address symptom clusters that may become intense or disruptive, especially those associated with moderate to severe physical discomfort. It is often used during phases when symptoms become more noticeable, offering supportive relief to help patients cope more steadily with difficult episodes.

Managing Inflammation and Swelling

Ketofan SR is relevant in conditions characterized by periods of heightened symptoms of swelling, heat, and inflammation in joints and muscles. By easing these manifestations and assisting in supporting functional stability, the medication contributes to a more manageable experience when symptoms interfere with routine activities.

Quick Fact: Symptomatic Support for Pain and Inflammation

Regulatory References

1. NIH MedlinePlus Drug Information

Ketofan SR (ketoprofen sustained-release) is governed by specific regulatory eligibility rules. Official documentation dictates which populations are strictly excluded and which require special caution:

Contraindicated Populations (Must Not Use)

• Patients with known hypersensitivity to ketoprofen, aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), especially if this includes aspirin-induced asthma or urticaria.
• Individuals with an active peptic ulcer or severe active gastrointestinal (GI) disease.
• Patients with severe heart failure, severe renal insufficiency, or severe hepatic insufficiency.
• Individuals undergoing treatment for peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
• Women who are 30 weeks pregnant or later (third trimester) due to the risk of fetal complications.

Conditional Use and Non-Established Groups

• Pediatric Patients: Use is not recommended, as safety and efficacy have not been established in children (typically under 12 or 18 years, depending on the regulatory label).
• Geriatric Patients: Use requires caution and close monitoring due to an increased risk of serious GI and renal adverse events.
• Pregnancy (20 to 30 weeks): Use should be limited to the lowest effective dose for the shortest duration possible due to the risk of fetal renal dysfunction.
• Breastfeeding: Use is not recommended as safety in nursing infants is not established.

Interactions with other medicines and products

The interaction profile of Ketoprofen, the active ingredient in Ketofan sr, is formally defined by official regulatory documents detailing both pharmacodynamic and pharmacokinetic patterns.

Documented Interaction Restrictions

The co-administration of Ketofan sr is contraindicated for the management of peri-operative pain associated with Coronary Artery Bypass Graft (CABG) surgery. Concomitant use with other NSAIDs or high-dose salicylates should be avoided due to the documented increase in the risk of serious gastrointestinal bleeding and ulceration.

Interacting Product Category	Official Outcome/Classification
Anticoagulants/Anti-platelet Agents	Increased risk of bleeding (Not Recommended)
Lithium or High-Dose Methotrexate	Increased plasma concentration of the co-administered drug
Diuretics, ACE Inhibitors/ARBs	Potential for reduction in renal blood flow
Corticosteroids or SSRIs	Increased risk of gastrointestinal bleeding

Other Documented Interactions

Official labeling documents that Ketoprofen does not induce drug-metabolizing enzymes. For the sustained-release formulation, co-administration with a high-fat meal results in a specific delay of approximately two hours in reaching maximum plasma concentration ( T max). Interactions with substances like alcohol and tobacco are documented to enhance the risk of gastrointestinal mucosal bleeding. Population-specific cautions note that elderly patients and individuals with chronic liver disease may face a higher risk of adverse outcomes from these interactions.

Inhibition of Cyclooxygenase Enzymes

Ketofan sr's action is governed entirely by its core mechanism as an inhibitor of the cyclooxygenase ( COX) enzyme system, resulting in the interruption of key biological signaling pathways involved in nociceptive and inflammatory signaling. The active compound, Ketoprofen, acts as a competitive, reversible inhibitor of both COX-1 and COX-2 enzymes. This action is the primary mechanistic domain, as it immediately blocks the enzymes from initiating the conversion of arachidonic acid into various prostanoids, which are the signaling molecules modulating inflammatory and nociceptive pathways.

Modulation within the Arachidonic Acid Cascade

The enzymatic blockade directly targets the arachidonic acid cascade, significantly reducing the synthesis of Prostaglandin E2 ( PGE2). PGE2 is a critical mediator that sensitizes peripheral nerve endings and regulates local blood vessel dynamics, and its reduction decreases the magnitude of specific physiological signaling at the cellular and tissue level.

Modulation of Nociceptive and Thermoregulatory Pathways

Ketofan sr engages pathways both locally and centrally. By limiting PGE2 production peripherally, it contributes to an elevation of the pain threshold of nerve endings. Centrally, the mechanism is used to modulate the hypothalamic thermoregulatory set-point by inhibiting PGE2 synthesis, which alters the physiological thermal signal.

Ketofan sr is an oral medication provided as a sustained-release capsule or tablet. The primary route of use is oral. The standard adult regimen for managing the signs and symptoms of chronic conditions, such as osteoarthritis and rheumatoid arthritis, is typically 200 mg taken once daily (qDay). The maximum recommended daily dose for this sustained-release formulation is limited to 200 mg.

To maintain the intended release profile of the medicine, the extended-release capsule or tablet must be swallowed whole. The dosage form should not be crushed, chewed, or divided before intake. Administration is generally permissible with or without food; however, consuming the dose with food, milk, or antacids is a measure used to help mitigate potential gastric discomfort.

There are dosing modifications for certain patient populations. For older adults, treatment initiation should begin at a lower dose than the standard adult regimen. Furthermore, patients with defined hepatic or renal impairment must adhere to reduced daily maximum doses. For example, the maximum dose is often restricted to 100 mg per day in cases of severe renal or specified hepatic dysfunction. This formulation is used for continuous, chronic symptomatic support and is not recommended for acute pain management.

Research evidence / Overview of studies for Ketofan sr

Evidence for Use in Chronic Inflammatory Conditions

Research examined the active compound in adult populations with conditions characterized by functional limitations, such as osteoarthritis and rheumatoid arthritis. Studies primarily included short-term and intermediate-term Randomized Controlled Trials (RCTs) conducted against an inactive control (placebo) or established standard treatments. Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations during the study period. Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations over the observation periods. These studies contribute to the broader evidence landscape.

While this evidence contributes to understanding symptom patterns, long-term effects are not fully established for this specific formulation. Furthermore, the available research is focused on symptomatic measurements and is not structured to assess whether the medicine modifies the underlying progression of chronic diseases.

Evidence for Use in Acute Pain Episodes

The active compound was studied for conditions involving periods of heightened symptoms, such as acute postoperative pain and primary dysmenorrhea. Studies explored short-term symptom changes, using research scenarios involving periods of increased symptom activity. Research examined outcomes describing episodic or acute changes over defined time intervals.

Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations over a short observation period. Research describes the measurement of the time required for initial change to occur. This evidence contributes to understanding symptom patterns.

Much of the evidence describing rapid changes in symptom intensity for acute, single-episode pain management was derived from trials using the immediate-release version of the active compound. Therefore, the sustained-release (SR) formulation is not the focus of most studies related to rapid changes in acute pain relief, and evidence for the SR form's use in short, single-episode pain is limited.

Evaluation of the Sustained-Release (SR) Formulation

The sustained-release formulation was evaluated in specific pharmacokinetic and bioequivalence studies. Research examined how the body processes the medication over time and studied the patterns of slow, prolonged release. These studies describe how the medication maintains consistent concentration in the body.

Data show patterns related to the active compound's concentration profile over a 24-hour period, indicating that a sustained release was observed in the studied population. This design was used in research exploring short-term symptom changes for chronic conditions where symptoms may vary in intensity throughout the day.

While the specific profile was observed, findings describe group patterns, not personal outcomes. Research does not determine whether an individual will respond similarly.

Long-Term Studies and Follow-up Data

Studies monitoring outcomes reflecting daily functioning or activity level were typically conducted for follow-up durations that were limited, primarily intermediate-term (e.g., up to 12 weeks). These research scenarios involved observational settings evaluating daily-life functioning for patients with conditions where symptoms may vary in intensity.

Evidence contributes to the broader evidence landscape for the drug class. Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations over these defined, limited time intervals.

There is limited information for long-term outcomes, and long-term effects for the sustained-release formulation are not fully established. The existing research provides context but not individual predictions regarding durability of response over many months or years.

Evidence in Special Populations

The active compound was observed in some studies that included older adult populations. Research examined how outcomes related to physical discomfort were measured and monitored in these groups to assess concentration and overall response patterns.

Findings describe patterns observed in the studies related to how symptoms evolved in the observed older adult populations. Findings describe patterns observed in these specific studies, contributing to understanding the compound's profile in this group.

However, data for certain groups, such as children, pregnant-related populations, or those with complex, specific comorbidities, remain insufficient. Subgroup findings are uncertain, and research has focused on the general adult patient cohort. The results apply only to the populations studied.

Areas of Research Uncertainty and Study Limitations

The evidence quality varies across studies, and some key research exploring short-term symptom changes involved modest sample sizes. Certainty remains low regarding long-term effects, as follow-up durations were limited in the core efficacy trials. Data for certain subgroups remain insufficient, and findings were mixed when comparing the active compound to certain other standard therapies in specific trial designs. The overall research structure provides context but evidence indicates that long-term effects are not fully established, and research is ongoing in certain areas.

Key Studies & References

1. Ketoprofen - LiverTox - Clinical and Research Information on Drug-Induced Liver Injury (NIH)

Common questions about Ketofan sr (FAQ)

Q: Can I drink alcohol while taking Ketofan sr?

A: Official labeling addresses the potential co-ingestion of Ketofan sr and alcohol. Regulatory information will explicitly state if alcohol should be avoided due to the risk of enhanced central nervous system (CNS) effects or other specific interactions. Specific restrictions are provided within the product information.

Q: What should I do if I miss a dose of Ketofan sr?

A: Regulatory documents provide specific information regarding a missed dose of Ketofan sr. This guidance specifies whether to take the missed dose right away, skip it and continue with the regular schedule, or if there are other precautions to consider. This information is available in the Dosage and Administration sections of the product documents.

Q: Does Ketofan sr cause drowsiness or affect my ability to drive?

A: The official product information specifies whether Ketofan sr has an influence on the ability to drive or operate machinery. Regulatory documents will describe the degree of influence, such as a 'minor' or 'moderate' effect, if applicable. Details on these potential effects can be reviewed in the Warnings and Precautions section.

Q: How should I store Ketofan sr?

A: Official labeling dictates the required storage conditions for Ketofan sr. This typically specifies the acceptable temperature range (e.g., 'controlled room temperature' or 'refrigerate') and whether the medicine needs protection from moisture or light. These details are available in the Storage and Handling sections of the regulatory documents.

Q: Can pregnant women take Ketofan sr?

A: Regulatory documents state the approved guidance regarding the use of Ketofan sr during pregnancy. The labeling includes available risk data and identifies any conditions where the product is not recommended for use. This information is detailed in the sections covering use in specific populations.

Q: Is Ketofan sr safe for children younger than 12 years old?

A: Official product information defines the specific age groups for which Ketofan sr is approved. If the drug is not indicated for a specific pediatric age group, the regulatory label generally notes that safety and efficacy have not been established in that population. This information is found in the Pediatric Use sections.

Q: Is it safe to take Ketofan sr every day for several months (long-term use)?

A: Regulatory documents specify warnings and precautions associated with the duration of treatment. The official labeling addresses the potential risks that may increase with prolonged use, or specifies a maximum recommended duration of therapy for continuous use. This information is contained within the Special Warnings and Precautions for Use section.

Official Storage and Disposal Guidelines

Ketofan SR (ketoprofen extended-release) must be stored strictly according to regulatory labeling to maintain its stability and effectiveness.

Storage Conditions:

Requirement	Specification
Temperature	Controlled Room Temperature (20^circ to 25 C / 68^circ to 77 F)
Handling	Protect from light and moisture; avoid extreme heat and freezing
Container	Keep in the original container, tightly closed
Safety	Keep out of the reach of children and pets

Disposal Protocol:

Unused or expired Ketofan SR should be disposed of through a dedicated drug take-back program whenever possible. If a take-back program is unavailable, the medication should be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a bag or container, and discarded in the household trash. The medication must not be flushed down a toilet or poured down a drain.